Cutaneous Reactions to BRAF Inhibitors
BRAF inhibitors, specifically vemurafenib and dabrafenib, are emerging as first-line treatment for unresectable and/or metastatic BRAF mutated melanoma due to their superior efficacy and improved survival statistics. While better tolerated than previously used treatment options, they carry high rates of cutaneous reactions, with most BRAF-inhibitor treated patients experiencing at least one cutaneous adverse effect.
Photosensitivity, various skin rashes, skin papillomas, hyperkeratosis, verrucal keratoses, and cutaneous squamous cell carcinomas (SCCs) are some of the more common cutaneous toxicities reported to date. These are typically managed symptomatically without need for dose reduction or discontinuation of the BRAF inhibitor. MEK inhibitors are now being used in combination with BRAF inhibitors to improve efficacy, prevent drug resistance, and lower the rate of cutaneous reactions. This chapter focuses on the cutaneous reactions associated with the RAF inhibitor sorafenib and the BRAF inhibitors vemurafenib and dabrafenib.
KeywordsBRAF inhibitor RAF inhibitor Metastatic melanoma Vemurafenib Dabrafenib
- Martinez-Garcia M, Banerji U, Albanell J, Bahleda R, Dolly S, Kraeber-Bodéré F, et al. First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors. Clin Cancer Res. 2012;18:4806–19.CrossRefPubMedGoogle Scholar
- Sinha R, Edmonds K, Newton-Bishop JA, Gore ME, Larkin J, Fearfield L. Cutaneous adverse events associated with vemurafenib in patients with metastatic melanoma: practical advice on diagnosis, prevention and management of the main treatment-related skin toxicities. Br J Dermatol. 2012;167:987–94.CrossRefPubMedGoogle Scholar